Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 449-468

  Jayaraman, Premkumar ^a,b   Sakharkar, Kishore R ^c   Lim, Chu Sing ^a,b   Siddiqi, Mohammad Imran ^d   Dhillon, Sarinder K ^e   Sakharkar, Meena K ^a,f  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c Central Drug Research Institute ^*  (Singapore)

^d CENTRAL DRUG RESEARCH INSTITUTE   (India)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Dihydrofolate reductase; DNA gyrase subunit B; Drug resistance; Hybrid compounds; Multi target inhibition; Rational drug design; Topoisomerase IV subunit B

Indexed keywords

5 ADENYLY BETA GAMMA IMIDODIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; ANTIBIOTIC PHYTOCHEMICAL CONJUGATE; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; CIPROFLOXACIN; CYCLOTHIALIDINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; EPIGALLOCATECHIN GALLATE; FLAVONOID; FOLIC ACID; GALLIC ACID; GALLIC ACID SULFADIAZINE CONJUGATE; GALLIC ACID SULFAMETHOXAZOLE CONJUGATE; METHOTREXATE; NOVOBIOCIN; PLANT MEDICINAL PRODUCT; PROTEIN PARE; PROTOCATECHUIC ACID; PROTOCATECHUIC ACID SULFADIAZINE CONJUGATE; PROTOCATECHUIC ACID SULFAMETHOXAZOLE CONJUGATE; PYROPHOSPHORIC ACID DERIVATIVE; SULFADIAZINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG; DNA TOPOISOMERASE IV; FOLIC ACID ANTAGONIST; GYRASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOGENESIS; COMPUTER MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG DESIGN; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE; HYDROGEN BOND; HYDROPHOBICITY; MATHEMATICAL ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; MUTAGENICITY; NONHUMAN; PREDICTION; PSEUDOMONAS AERUGINOSA; REPRODUCTIVE TOXICITY; SIMULATION; STRUCTURE ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR DYNAMICS; STATIC ELECTRICITY; TOXICITY;

ADENOSINE TRIPHOSPHATE; ANTI-BACTERIAL AGENTS; BINDING SITES; DNA TOPOISOMERASE IV; DRUG DESIGN; FOLIC ACID ANTAGONISTS; METHOTREXATE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PSEUDOMONAS AERUGINOSA; STATIC ELECTRICITY; TETRAHYDROFOLATE DEHYDROGENASE; TOPOISOMERASE II INHIBITORS;

EID: 84879158788     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S43964     Document Type: Article

References (64)

1. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8): 419-426.
2. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4): 582-610.
3. Mesaros N, Nordmann P, Plésiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007;13(6):560-578.
4. Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS 2nd. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy. 2011;31(6):598-608.
5. Johnson SJ, Ernst EJ, Moores KG. Is double coverage of gramnegative organisms necessary? Am J Health Syst Pharm. 2011;68(2): 119-124.
6. Pokrovskaya V, Baasov T. Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin Drug Discov. 2010;5(9):883-902.
7. Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12(1-2):34-42.
8. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.
9. Bremner JB, Ambrus JI, Samosorn S. Dual action-based approaches to antibacterial agents. Curr Med Chem. 2007;14(13):1459-1477.
10. Morphy R, Rankovic Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr Pharm Des. 2009;15(6):587-600.
11. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9(15):641-651.
12. Pokrovskaya V, Belakhov V, Hainrichson M, Yaron S, Baasov T. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J Med Chem. 2009;52(8):2243-2254.
13. Ball AR, Casadei G, Samosorn S, et al. Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chemi Biol. 2006;1(9):594-600.
14. Labischinski H, Cherian J, Calanasan C, Boyce RS, Inventors. Hybrid antimicrobial compounds and their use. United States patent US WO/2010/025906. March 11, 2010.
15. Ma XH, Shi Z, Tan C, et al. In-silico approaches to multi-target drug discovery: computer aided multi-target drug design, multi-target virtual screening. Pharm Res. 2010;27(5):739-749.
16. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminform. 2011;3:33.
17. Koch W, Holthausen MC. A Chemist's Guide to Density Functional Theory. Weinheim, Germany: Wiley-VCH; 2000.
18. Zhao YH, Abraham MH, Le J, et al. Rate-limited steps of human oral absorption and QSAR studies. Pharm Res. 2002;19(10): 1446-1457.
19. Sander T, Freyss J, von Korff M, Reich JR, Rufener C. OSIRIS, an entirely in-house developed drug discovery informatics system. J Chem Inf Model. 2009;49(2):232-246.
20. Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006;49(11): 3315-3321.
21. Wang R, Fang X, Lu Y, Wang S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known threedimensional structures. J Med Chem. 2004;47(12):2977-2980.
22. Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins. 2004;57(4):678-683.
23. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. J Chem Phys. 1995;103(19): 8577-8593.
24. Klamt A. Conductor-like screening model for real solvents: a new approach to the quantitative calculation of solvation phenomena. J Phys Chem. 1995;99(7):2224-2235.
25. Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. parameterization and validation. J Comput Chem. 2002;23(16):1623-1641.
26. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25(9): 1157-1174.
27. Hooft RW, Sander C, Vriend G. Positioning hydrogen atoms by optimizing hydrogen-bond networks in protein structures. Proteins. 1996;26(4):363-376.
28. Krieger E, Nielsen JE, Spronk CA, Vriend G. Fast empirical pKa prediction by Ewald summation. J Mol Graph Model. 2006;25(4): 481-486.
29. Xie L, Xie L, Kinnings SL, Bourne PE. Novel Computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol. 2012;52(1):361-379.
30. Spina M, Cuccioloni M, Mozzicafreddo M, et al. Mechanism of inhibition of wt-dihydrofolate reductase from E. coli by tea epigallocatechin-gallate. Proteins. 2008;72(1):240-251.
31. Gradisar H, Pristovsek P, Plaper A, Jerala R. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J Med Chem. 2007;50(2):264-271.
32. Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol. 2008;8(5):574-581.
33. Jayaraman P, Sakharkar KR, Sing LC, Chow VT, Sakharkar MK. Insights into antifolate activity of phytochemicals against Pseudomonas aeruginosa. J Drug Target. 2011;19(3):179-188.
34. Sakharkar MK, Jayaraman P, Soe WM, Chow VT, Sing LC, Sakharkar KR. In vitro combinations of antibiotics and phytochemicals against Pseudomonas aeruginosa. J MicrobioI Immunol Infect. 2009; 42(5):364-370.
35. Marques SM, Enyedy EA, Supuran CT, Krupenko NI, Krupenko SA, Santos MA. Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Medicinal Chem. 2010;18(14):5081-5089.
36. Brvar M, Perdih A, Oblak M, Masic LP, Solmajer T. In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B. Bioorg Med Chem Lett. 2010;20(3):958-962.
37. Lerner MG, Bowman AL, Carlson HA. Incorporating dynamics in E. coli dihydrofolate reductase enhances structure-based drug discovery. J Chem Inf Model. 2007;47(6):2358-2365.
38. Schechner M, Sirockin F, Stote RH, Dejaegere AP. Functionality maps of the ATP binding site of DNA gyrase B: generation of a consensus model of ligand binding. J Med Chem. 2004;47(18):4373-4390.
39. Manly CJ, Chandrasekhar J, Ochterski JW, Hammer JD, Warfield BB. Strategies and tactics for optimizing the hit-to-lead process and beyond-a computational chemistry perspective. Drug Discov Today. 2008;13(3-4):99-109.
40. Matter H, Baringhaus KH, Naumann T, Klabunde T, Pirard B. Computational approaches towards the rational design of drug-like compound libraries. Comb Chem High Throughput Screen. 2001; 4(6):453-475.
41. Lipinski CA. Lead-and drug-like compounds: the rule-of-f ive revolution. Drug Discov Today Technol. 2004;1(4):337-341.
42. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-2623.
43. Maiti R, Van Domselaar GH, Zhang H, Wishart DS. SuperPose: a simple server for sophisticated structural superposition. Nucleic Acids Res. 2004;32(Web Server issue):W590-W594.
44. Lessa JA, Mendes IC, da Silva PR, et al. 2-Acetylpyridine thiosemicarbazones: cytotoxic activity in nanomolar doses against malignant gliomas. Eur J Med Chem. 2010;45(12):5671-5677.
45. Liu XH, Chen PQ, Wang BL, Li YH, Wang SH, Li ZM. Synthesis, bioactivity, theoretical and molecular docking study of 1-cyano-Nsubstituted-cyclopropanecarboxamide as ketol-acid reductoisomerase inhibitor. Bioorg Med Chem Lett. 2007;17(13):3784-3788.
46. Nascimento EC, Martins JB. Electronic structure and PCA analysis of covalent and non-covalent acetylcholinesterase inhibitors. J Mol Model. 2011;17(6):1371-1379.
47. Oblak M, Kotnik M, Solmajer T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem. 2007; 14(19):2033-2047.
48. Bellon S, Parsons JD, Wei Y, et al. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother. 2004;48(5):1856-1864.
49. Cody V, Schwalbe CH. Structural characteristics of antifolate dihydrofolate reductase enzyme interactions. Crystallogr Rev. 2006; 12(4):301-333.
50. Agarwal P, Searls DB. Literature mining in support of drug discovery. Brief Bioinform. 2008;9(6):479-492.
51. Yang Y, Adelstein SJ, Kassis AI. Target discovery from data mining approaches. Drug Discov Today. 2009;14(3-4):147-154.
52. Park K, Kim D. Binding similarity network of ligand. Proteins. 2008; 71(2):960-971.
53. Durrant JD, Amaro RE, Xie L, et al. A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput Biol. 2010;6(1).
54. Jayaraman P, Sakharkar MK, Lim CS, Tang TH, Sakharkar KR. Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro. Int J Biol Sci. 2010;6(6):556-558.
55. Gibbons S, Moser E, Kaatz GW. Catechin gallates inhibit multidrug resistance (MDR) in Staphylococcus aureus. Planta Med. 2004;70(12): 1240-1242.
56. Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine. 2008;15(8):639-652.
57. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005;26(5):343-356.
58. Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008;13(19-20):894-901.
59. Lewis K, Ausubel FM. Prospects for plant-derived antibacterials. Nat Biotechnol. 2006;24(12):1504-1507.
60. Bermingham A, Derrick JP. The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. Bioessays. 2002;24(7):637-648.
61. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol. 2006;71(7):941-948.
62. Köhler T, Kok M, Michea-Hamzehpour M, et al. Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996;40(10):2288-2290.
63. Chusri S, Villanueva I, Voravuthikunchai SP, Davies J. Enhancing antibiotic activity: a strategy to control Acinetobacter infections. J Antimicrob Chemother. 2009;64(6):1203-1211.
64. Rogers GB, Carroll MP, Bruce KD. Enhancing the utility of existing antibiotics by targeting bacterial behaviour? Brit J Pharmacology. 2012;165(4):845-857.